Impact of pre-neoadjuvant radioactive iodine seed marking on pathologic complete response and survival in early-stage breast cancer patients
Neoadjuvant therapy (NAT) has become the standard treatment for patients with locally advanced breast cancer and stage II–III HER2-positive (HER2+) or triple-negative breast cancer (TNBC)[1][1],[2][2]. It is essential to accurately mark the primary breast tumor and positive axillary lymph nodes (
Authors
- Xiaowei Qi (ORCID: https://orcid.org/0000-0001-6650-3629)
- Zhao Bi
- Qiuchen Zhao
- Qi Zhang
- Rongrong Zhao
- Yongsheng Wang
- Yihao Geng
- Pengfei Qiu
- Zhiqiang Shi
Institutions
- Army Medical University (CN)
- Cancer Research UK Cambridge Center (GB)
- Shandong Tumor Hospital (CN)
- Southwest Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Cancer Biology and Medicine
- Published
- 2025-12-26
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2025.0578
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- National Science and Technology Major Project